Beigene (06160.HK)(688235.SH) announced that its self-developed anti-PD-1 antibody drug, Bai Ze An (Tislelizumab injection), and BTK inhibitor Bai Yue Ze (Zevalin capsules) have both been added with three indications and one indication respectively to the national medical insurance catalog; Luye Pharma (02186.HK) has introduced the product Bai Tuo Wei (Galeterone injection), which has had one additional indication included in the national medical insurance catalog; Amgen has successfully renewed the authorization for the introduced product Kai Luo Si (Carfilzomib injection). The national medical insurance catalog will officially be implemented starting January 1, 2025.
The company stated that the new indications for its products Bai Ze An, Bai Yue Ze, and the collaborated product Bai Tuo Wei, along with the successful renewal of Kai Luo Si in the national medical insurance catalog, reflect the national healthcare security administration's support and recognition of innovative drugs that have high clinical value and reasonable prices. Inclusion in the national medical insurance catalog will help the company further improve the affordability and accessibility of these products for patients, and will also facilitate the market promotion and sales of these products, having a positive impact on the long-term operation and development of the company.
Beigene is currently priced at 125.3 yuan, up 2.54%, with a trading volume of 0.7194 million shares, involving 89.5428 million yuan.
